BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Since its discovery by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, it has generated enormous interest in the peptide research community — and enormous frustration. Despite hundreds of animal studies demonstrating remarkable healing properties across nearly every organ system, human clinical trial data remains extremely limited.
This article provides a comprehensive, evidence-based overview of where BPC-157 research actually stands in 2026 — what we know, what we don't, and what would need to happen for this peptide to move toward clinical use.
The Research Landscape: A Peptide Without a Pharma Sponsor
BPC-157's research profile is unusual. The vast majority of published studies — estimated at over 100 peer-reviewed papers — originate from a single research group at the University of Zagreb, Croatia. While this body of work is substantial and internally consistent, the lack of independent replication from other laboratories is a significant limitation that the scientific community has noted repeatedly.
The peptide's amino acid sequence (GEPPPGKPADDAGLV, molecular weight 1,419 Da) is a 15-amino acid fragment of a larger protein called BPC (Body Protection Compound) that is naturally present in human gastric juice. It is remarkably stable in gastric fluid — remaining intact for over 24 hours — which is unusual for a peptide and has implications for oral bioavailability (PMID: 21548867).
Existing Human Trial Data
Phase II — Inflammatory Bowel Disease (Croatia)
The most significant human data comes from a Phase II clinical trial for ulcerative colitis conducted in Croatia under the designation PL-14736 (also referred to as PL-10 and PLD-116). This trial, referenced across multiple publications by the Sikiric group, reportedly demonstrated efficacy in inflammatory bowel disease with no toxicity (PMID: 22300085). However, the full trial data has never been published in a standalone clinical paper, making independent evaluation difficult.
Phase I — Safety & Pharmacokinetics (NCT02637284)
In December 2015, a Phase I trial was registered on ClinicalTrials.gov (NCT02637284) by PharmaCotherapia d.o.o. The study aimed to assess safety and pharmacokinetics of PCO-02 (active ingredient: BPC-157) in 42 healthy volunteers aged 18–35. The trial status is listed as "Unknown" — it was reportedly cancelled in 2016, and no results were ever published.
2025 Pilot Study — IV Safety in Humans
The most recent human data is a 2025 pilot study by Lee and Burgess, published in Alternative Therapies in Health and Medicine (PMID: 40131143). This small study administered intravenous BPC-157 at doses up to 20 mg in 2 healthy adults and reported no adverse effects. While encouraging for basic safety, a two-person pilot study without a control group provides very limited evidence.
Retrospective Knee Pain Data
A small retrospective study evaluated 12 patients who received BPC-157 injections for knee pain, suggesting potential benefit. However, retrospective, uncontrolled studies of this size cannot establish efficacy.
Bottom line: As of February 2026, there is no published, peer-reviewed, randomized controlled trial of BPC-157 in humans for any indication.
Key Animal Research Results by System
Despite the human data gap, the preclinical evidence for BPC-157 is extensive. Here are the most significant findings organized by body system.
Gastrointestinal Healing
This is where BPC-157 research began, and the evidence is most robust. Studies demonstrate:
- Gastric ulcer healing — Accelerated healing of various ulcer models including NSAID-induced, stress-induced, and cysteamine-induced ulcers (PMID: 21548867)
- Intestinal anastomosis repair — Enhanced healing of surgical intestinal connections in rats (PMID: 17713731)
- Fistula healing — Promoted closure of gastrointestinal fistulas in animal models (PMID: 32329684)
- Inflammatory bowel disease models — Reduced inflammation and improved tissue integrity in colitis models
- Short bowel adaptation — Improved adaptive response after massive intestinal resection, including increased villus height, crypt depth, and muscle thickness
The gut-healing effects align with BPC-157's origin as a gastric juice peptide and represent the most biologically plausible therapeutic application. For more on the overall benefits profile, see our BPC-157 Benefits Guide.
Tendon, Ligament & Musculoskeletal Repair
BPC-157's effects on connective tissue healing have driven much of its popularity in sports medicine:
- Achilles tendon transection — Full recovery in transected rat Achilles tendons with BPC-157 treatment (PMID: 14554208)
- Tendon fibroblast activation — Promoted outgrowth, survival under stress, and migration of tendon fibroblasts via the FAK-paxillin signaling pathway (PMID: 21030672)
- Growth hormone receptor upregulation — Enhanced GH receptor expression in tendon fibroblasts, potentially improving the healing response (PMC6271067)
- Ligament healing — Improved medial collateral ligament healing in rats
A 2025 systematic review in orthopaedic sports medicine confirmed BPC-157's consistent positive effects in animal musculoskeletal models while noting the complete absence of human clinical data (PMC12313605).
Neuroprotection & Brain Injury
BPC-157's effects on the nervous system are mediated through what researchers describe as the "brain-gut axis":
- Traumatic brain injury (TBI) — Improved consciousness/death ratios in mice when administered within minutes of TBI; beneficial effects observed even with pre-injury dosing (PMID: 19931318)
- Spinal cord injury — Rescued tail function, reduced axonal necrosis, demyelination, and cyst formation after spinal cord compression in rats
- Peripheral nerve regeneration — Promoted nerve regrowth after transection
- Dopamine system modulation — Counteracted disturbances from receptor blockade, supersensitivity development, and nigrostriatal damage (PMID: 34380875)
- Hippocampal ischemia/reperfusion — Protected against hippocampal damage in ischemia models
The comprehensive review by Sikiric et al. on BPC-157 and the central nervous system (PMID: 27138887) outlines the peptide's broad neuroprotective profile, including potential implications for stroke, schizophrenia, and encephalopathy.
Cardiovascular Protection
- Myocardial infarction — Protected against isoprenaline-induced MI in rats, with reduced cardiac damage markers
- Pulmonary hypertension — Both prevented and reversed monocrotaline-induced pulmonary hypertension in rats
- Arrhythmias — Antiarrhythmic effects, including counteracting digitalis-induced ventricular tachycardia
- Thrombosis — Prevention and reversal demonstrated in animal models (PMID: 36359218)
Liver Protection
- Hepatoprotective effects — Protected against liver damage from restraint stress, bile duct ligation, hepatic artery ligation, and carbon tetrachloride (CCl4) toxicity (PMID: 7901724)
- Radiation-induced liver injury — Reduced apoptosis and lipid accumulation via KLF4 upregulation (PMID: 36228773)
- Alcohol-related damage — Attenuated liver lesions in chronic alcohol models
For practical information on how researchers have applied these findings, see our BPC-157 Dosing Guide and BPC-157 Results Timeline.
Ready to buy? Compare verified vendors on our best BPC-157 sources page, or browse all coupon codes for up to 50% off.
